Nkarta (NKTX) Current Assets (2019 - 2026)
Nkarta's quarterly Current Assets came in at $235.9 million in Q1 2026, down 13.13% year-on-year from $271.6 million in Q1 2025, and down 16.5% quarter-over-quarter from $282.5 million in Q4 2025.
Nkarta has reported Current Assets for 8 years, with the latest figure at $235.9 million in Q1 2026.
- For the quarter ending Q1 2026, Current Assets fell 13.13% year-over-year to $235.9 million; the trailing twelve-month figure through Mar 2026 stood at $235.9 million (down 13.13% YoY), and the FY2025 full-year result was $282.5 million, up 3.36% from the prior year.
- Current Assets for Q1 2026 stood at $235.9 million, down from $282.5 million in the prior quarter.
- The five-year high for Current Assets was $442.8 million in Q1 2024, with the low at $223.2 million in Q1 2022.
- Average Current Assets over 5 years is $310.0 million, with a median of $289.3 million recorded in 2025.
- Year-over-year, Current Assets soared 51.5% in 2022 and tumbled 38.67% in 2025.
- Tracing NKTX's Current Assets over 5 years: stood at $360.7 million in 2022, then retreated by 29.84% to $253.1 million in 2023, then rose by 8.01% to $273.3 million in 2024, then grew by 3.36% to $282.5 million in 2025, then slipped by 16.5% to $235.9 million in 2026.
- The last three Current Assets figures came in at $235.9 million (Q1 2026), $282.5 million (Q4 2025), and $289.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 10.37 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 37.31 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.25 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 73.04 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 3.59 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 11.73 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 18.21 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.22 Bn |
| 10 | Nkarta | 232.80 Mn | 232.80 Mn | - | 235.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 235.89 Mn |
| Dec 31, 2025 | 282.51 Mn |
| Sep 30, 2025 | 289.28 Mn |
| Jun 30, 2025 | 296.57 Mn |
| Mar 31, 2025 | 271.55 Mn |
| Dec 31, 2024 | 273.34 Mn |
| Sep 30, 2024 | 290.15 Mn |
| Jun 30, 2024 | 331.80 Mn |
| Mar 31, 2024 | 442.78 Mn |
| Dec 31, 2023 | 253.07 Mn |
| Sep 30, 2023 | 281.19 Mn |
| Jun 30, 2023 | 286.74 Mn |
| Mar 31, 2023 | 332.19 Mn |
| Dec 31, 2022 | 360.69 Mn |
| Sep 30, 2022 | 400.92 Mn |
| Jun 30, 2022 | 417.38 Mn |
| Mar 31, 2022 | 223.22 Mn |
| Dec 31, 2021 | 245.78 Mn |
| Sep 30, 2021 | 264.64 Mn |
| Jun 30, 2021 | 283.94 Mn |
| Mar 31, 2021 | 302.23 Mn |
| Dec 31, 2020 | 318.84 Mn |
| Sep 30, 2020 | 333.39 Mn |
| Jun 30, 2020 | 22.30 Mn |
| Dec 31, 2019 | 37.47 Mn |